JP7460598B2 - 膝および／または股関節痛の安全で効果的な処置用の医薬組成物 - Google Patents

膝および／または股関節痛の安全で効果的な処置用の医薬組成物 Download PDF

Info

Publication number
JP7460598B2
JP7460598B2 JP2021505954A JP2021505954A JP7460598B2 JP 7460598 B2 JP7460598 B2 JP 7460598B2 JP 2021505954 A JP2021505954 A JP 2021505954A JP 2021505954 A JP2021505954 A JP 2021505954A JP 7460598 B2 JP7460598 B2 JP 7460598B2
Authority
JP
Japan
Prior art keywords
pain
pharmaceutical composition
antibody
ngf
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021505954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533142A (ja
JP2021533142A5 (https=
JPWO2020033872A5 (https=
Inventor
グレゴリー・ゲバ
ポーラ・デーキン
スティーヴン・ディマルティノ
ハイタオ・ガオ
ジェニファー・マロニー
ジョン・デイヴィス
キャサリン・ステーマン－ブリーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2021533142A publication Critical patent/JP2021533142A/ja
Publication of JP2021533142A5 publication Critical patent/JP2021533142A5/ja
Publication of JPWO2020033872A5 publication Critical patent/JPWO2020033872A5/ja
Application granted granted Critical
Publication of JP7460598B2 publication Critical patent/JP7460598B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2021505954A 2018-08-10 2019-08-09 膝および／または股関節痛の安全で効果的な処置用の医薬組成物 Active JP7460598B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862717435P 2018-08-10 2018-08-10
US62/717,435 2018-08-10
US201862764816P 2018-08-15 2018-08-15
US62/764,816 2018-08-15
PCT/US2019/045970 WO2020033872A1 (en) 2018-08-10 2019-08-09 A pharmaceutical composition for safe and effective treatment of knee and/or hip pain

Publications (4)

Publication Number Publication Date
JP2021533142A JP2021533142A (ja) 2021-12-02
JP2021533142A5 JP2021533142A5 (https=) 2022-08-12
JPWO2020033872A5 JPWO2020033872A5 (https=) 2022-08-12
JP7460598B2 true JP7460598B2 (ja) 2024-04-02

Family

ID=67811008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021505954A Active JP7460598B2 (ja) 2018-08-10 2019-08-09 膝および／または股関節痛の安全で効果的な処置用の医薬組成物

Country Status (10)

Country Link
US (2) US11472870B2 (https=)
EP (1) EP3833687A1 (https=)
JP (1) JP7460598B2 (https=)
KR (1) KR20210043624A (https=)
CN (1) CN112839956A (https=)
AU (1) AU2019318556A1 (https=)
CA (1) CA3108697A1 (https=)
IL (1) IL280550B2 (https=)
MX (1) MX2021001549A (https=)
WO (1) WO2020033872A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7532290B2 (ja) * 2021-03-09 2024-08-13 エヌ・ティ・ティ・コミュニケーションズ株式会社 患者追跡調査支援システム、患者追跡調査支援方法、支援制御装置、端末装置およびプログラム
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
US20240002491A1 (en) * 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535929A (ja) 2005-04-11 2008-09-04 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨関節炎疼痛を治療するための方法とそれを含有する組成物
US20110014208A1 (en) 2007-08-10 2011-01-20 Regeneron Pharmaceuticals, Inc. Method of Treating Osteoarthritis with an Antibody to NGF
JP2013507385A (ja) 2009-10-09 2013-03-04 アムジェン インコーポレイテッド 選択的ｎｇｆ経路インヒビターとしてのヒト抗ｎｇｆ中和抗体
WO2018102294A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for averting opioid addiction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
BRPI0815370B8 (pt) 2007-08-10 2021-05-25 Regeneron Pharma anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica
PE20130203A1 (es) 2010-03-17 2013-03-24 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
BR112013008366B1 (pt) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
EP2859018B1 (en) * 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535929A (ja) 2005-04-11 2008-09-04 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨関節炎疼痛を治療するための方法とそれを含有する組成物
US20110014208A1 (en) 2007-08-10 2011-01-20 Regeneron Pharmaceuticals, Inc. Method of Treating Osteoarthritis with an Antibody to NGF
JP2013507385A (ja) 2009-10-09 2013-03-04 アムジェン インコーポレイテッド 選択的ｎｇｆ経路インヒビターとしてのヒト抗ｎｇｆ中和抗体
WO2018102294A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for averting opioid addiction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Maloney, J. et al.，Efficacy and Safety of Fasinumab for Osteoarthritic Pain in Patients with Moderate to Severe Osteoarthritis of the Knees or Hips.，ACR Meeting Abstract [online]，2016 ACR/ARFP Annual Meeting，2016年09月28日，Abstract Number 295，https://acrabstracts.org/abstract/efficacy-and-safety-of-fasinumab-for-osteoarthritic-pain-in-patients-with-moderate-to-severe-osteoarthritis-of-the-knees-or-hips/
Osteoarthritis and Cartilage，2017年04月，Vol.25 No.3(Suppl. 1) ，S56-S57 (Article No.73)

Also Published As

Publication number Publication date
US11472870B2 (en) 2022-10-18
JP2021533142A (ja) 2021-12-02
KR20210043624A (ko) 2021-04-21
CA3108697A1 (en) 2020-02-13
IL280550B1 (en) 2025-02-01
US20220041708A1 (en) 2022-02-10
MX2021001549A (es) 2021-04-13
WO2020033872A1 (en) 2020-02-13
IL280550B2 (en) 2025-06-01
EP3833687A1 (en) 2021-06-16
IL280550A (en) 2021-03-25
CN112839956A (zh) 2021-05-25
US20200048337A1 (en) 2020-02-13
AU2019318556A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
JP5537740B2 (ja) Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法
JP2024054237A (ja) 抗ｉｌ－１３抗体を使用する、ｉｌ－１３活性が有害である疾患の治療方法
US20220041708A1 (en) Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain
US11491222B2 (en) Method of treating lower back pain
KR20210122810A (ko) 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
US20230183362A1 (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
US20250011408A1 (en) Methods and compositions for reducing centralized pain
RU2786232C2 (ru) Фармацевтическая композиция для безопасного и эффективного лечения боли колена и/или тазобедренного сустава
US20240002491A1 (en) Methods for selecting patients for treatment with an ngf antagonist
EA044062B1 (ru) Фармацевтическая композиция для предотвращения опиоидной зависимости
KR20240008298A (ko) 항 il-13 항체를 사용한 아토피성 피부염을 치료하는 방법
HK40100361A (zh) 用抗il-13抗体治疗特应性皮炎的方法
HK40011843A (en) A pharmaceutical composition for averting opioid addiction
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240321

R150 Certificate of patent or registration of utility model

Ref document number: 7460598

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150